Identification of Two Gene Variants Associated With Risk of Advanced Fibrosis in Patients With Chronic Hepatitis C

Gastroenterology

Volumn 130, Issue 6, 2006, Pages 1679-1687

  Huang, Hongjin ^a   Shiffman, Mitchell L ^b   Cheung, Ramsey C ^c   Layden, Thomas J ^d   Friedman, Scott ^e   Abar, Olivia T ^a   Yee, Linda ^f   Chokkalingam, Anand P ^a   Schrodi, Steven J ^a   Chan, Jason ^a   Catanese, Joseph J ^a   Leong, Diane U ^a   Ross, David ^a   Hu, Xiaolan ^a   Monto, Alexander ^f   McAllister, Linda B ^a   Broder, Samuel ^g   White, Thomas ^a   Sninsky, John J ^a   Wright, Teresa L ^f  

^a CELERA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CELERA GENOMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; DEAD BOX POLYPEPTIDE 5; DEAD BOX PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

EID: 33646351020     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.02.032     Document Type: Article

References (37)

1. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. June 10-12, 2002. Hepatology 36 (2002) S3-S20
2. Strader D.B., Wright W., Thomas D.L., and Seeff L.B. AASLD practice guideline. diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
3. Poynard T., Bedossa P., Opolon P., The OBSVIRC, METAVIR, CLINIVIR, and and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 (1997) 825-832
4. Wright M., Goldin R., Fabre A., Lloyd J., Thomas H., Trepo C., Pradat P., and Thursz M. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection. a cross-sectional and longitudinal study. Gut 52 (2003) 574-579
5. Ramesh S., and Sanyal A.J. Hepatitis C and nonalcoholic fatty liver disease. Semin Liver Dis 24 (2004) 399-413
6. Bataller R., North K.E., and Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis. a critical appraisal. Hepatology 37 (2003) 493-503
7. Hirschhorn J.N., Lohmueller K., Byrne E., and Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 4 (2002) 45-61
8. Colhoun H.M., McKeigue P.M., and Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 361 (2003) 865-872
9. Lohmueller K.E., Pearce C.L., Pike M., Lander E.S., and Hirschhorn J.N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33 (2003) 177-182
10. Risch N.J. Searching for genetic determinants in the new millennium. Nature 405 (2000) 847-856
11. Brunt E.M. Grading and staging the histopathological lesions of chronic hepatitis. the Knodell histology activity index and beyond. Hepatology 31 (2000) 241-246
12. Monto A., Patel K., Bostrom A., Pianko S., Pockros P., McHutchison J.G., and Wright T.L. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 39 (2004) 826-834
13. Bedossa P., and French METAVIR Cooperative Group. Inter- and intraobserver variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 20 (1994) 15-20
14. Skinner H.A., and Sheu W.J. Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol 43 (1982) 1157-1170
15. Germer S., Holland M.J., and Higuchi R. High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res 10 (2000) 258-266
16. Fisher R.A. Statistical methods for research workers. 12th ed. (1954), Oliver & Lloyd, Edinburgh
17. Breslow N.E., and Day N.E. Statistical methods in cancer research. Volume I. The analysis of case-control studies. IARC Sci Publ 32 (1980) 5-338
18. The International HapMap Consortium. The International HapMap Project. Nature 426 (2003) 789-796
19. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview. analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
20. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., and Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70 (2002) 425-434
21. Yoo J., Seo B., and Kim Y. SNPAnalyzer. web-based workbench for the SNP analysis. (http://istech21.com/en/service/snp_a01.html). Genomic Inform 14 (2003) 591-592
22. Chen J., Germer S., Higuchi R., Berkowitz G., Godbold J., and Wetmur J.G. Kinetic polymerase chain reaction on pooled DNA. a high-throughput, high-efficiency alternative in genetic epidemiological studies. Cancer Epidemiol Biomarkers Prev 11 (2000) 131-136
23. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 36 (2002) S35-S46
24. Zeuzem S., Feinman S.V., Rasenack J., Heathcote E.J., Lai M.Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., and Brunda M.J. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343 (2000) 1666-1672
25. Marcellin P., Asselah T., and Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 36 (2002) S47-S56
26. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., Feng Z.Z., Reddy K.R., and Schiff E.R. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002) 2614-2618
27. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
28. Afdal N.H., and Nunes D. Evaluation of liver fibrosis. a concise review. Am J Gastroenterol 99 (2004) 1160-1174
29. Rousselet M.C., Michalak S., Dupre F., Croue A., Bedossa P., Saint-Andre J.P., and Cales P. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 41 (2005) 257-264
30. Rocak S., and Linder P. DEAD-box proteins. the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol 5 (2004) 232-241
31. Rossler O.G., Hloch P., Schutz N., Weitzenegger T., and Stahl H. Structure and expression of the human p68 RNA helicase gene. Nucleic Acids Res 28 (2000) 932-939
32. Goh P.Y., Tan Y.J., Lim S.P., Tan Y.H., Lim S.G., Fuller-Pace F., and Hong W. Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. J Virol 78 (2004) 5288-5298
33. Bataller R., Paik Y.H., Lindquist J.N., Lemasters J.J., and Brenner D.A. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126 (2004) 529-540
34. Mazzocca A., Sciammetta S.C., Carloni V., Cosmi L., Annunziato F., Harada T., Abrignani S., and Pinzani M. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem 280 (2005) 11329-11339
35. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
36. Bonnefont J.P., Djouadi F., Prip-Buus C., Gobin S., Munnich A., and Bastin J. Carnitine palmitoyltransferases 1 and 2. biochemical, molecular and medical aspects. Mol Aspects Med 25 (2004) 495-520
37. Gobin S., Thuillier L., Jogl G., Faye A., Tong L., Chi M., Bonnefont J.P., Girard J., and Prip-Buus C. Functional and structural basis of carnitine palmitoyltransferase 1A deficiency. J Biol Chem 278 (2003) 50428-50434